Biotech "Tweets of the Week" for December 8-12, 2014
Independent no More: Cubist Sold to Merck for $9.5B http://t.co/NX0EWfenJm $CBST $MRK
— Ben Fidler (@BentheFidler) December 8, 2014
HAH! RT @MikeNGladstone: NCI's Steve Rosenberg: "sadly, I have no personal financial conflicts of interest to report"
#ASH14
— Michael Koeris (@mkoeris) December 7, 2014
#biotech information/news overload last couple of days. Mostly positive.
$BLUE cured 4/4 patients - simply amazing... real advance in medicine...
— Ian Estepan (@ianestepan) December 8, 2014
Closed $blue for almost 45% gain. Very pleased. Probably goes higher, but I'm content. Added to $cnat today. I guess I also like to suffer?
— Joe (@Drchik23) December 8, 2014
Per usual, I was wrong. Thought good news was baked into $BLUE. Happy to be wrong in this case though. Keep up the amazing work @bluebirdbio
— Bobby Shea (@robertcshea) December 8, 2014
My whole stream just exploded with tweets about one stock... and for good reason $BLUE
— BioBreakout (@BioBreakout) December 8, 2014
Imagine having your hemoglobin returned to normal and not needing constant transfusions? That's huge. #ash14
— Sally Church (@MaverickNY) December 8, 2014
Same people called $AGIO too expensive in the $40's. This market rewards quality science quickly, good stocks won't wait for you. $BLUE
— Brad Loncar (@bradloncar) December 8, 2014
.@bradloncar summary: Pharma pays some MDs. Some of the paid MDs prescribe a lot of meds, other don't, many high prescribers not paid at all
— Dr. Tro Kalayjian (@TroKalayjianCRG) December 8, 2014
I just $BLUE my brains out for missing this run
— Rick (@Skipjackrick) December 9, 2014
Sold $mdvn lost 1.10 this time. Looks like nothing spectacular on poster. Been a big winner this year. Look for next one.
— Festo (@Festo50) December 9, 2014
$ABBV in a nice tight range today. Odd given the overall volatility in market.
— David Sobek (@dsobek) December 9, 2014
Just checked indexes. Didn't realize there was a selloff underway. Blissful biotech's ignoring them.
— avidresearch (@avidresearch) December 9, 2014
If you don’t have the time or ability to know your investments better than most, then you should be more diversified.
— MicroCapClub (@iancassel) December 9, 2014
If you are NOT interested in my greedy investing alter ego and prefer to hear about my lab's science follow @ChemosensoryLab
— Alfredo Fontanini (@AF_biotech) December 10, 2014
market punishing $MRK for $CBST IP issues?
— Juan P. Serrate, DVM (@JPZaragoza1) December 9, 2014
"Drug discovery is a pretty humbling experience"MT @dbsable Classic @Dereklowe understatement
http://t.co/XmbJ6jjpqg pic.twitter.com/WSZQsbB08n
— Laura Strong (@scientre) December 10, 2014
Two new biotech-related ETFs start trading next week. $BBC Biotech Clinical Trials Fund & $BBP Biotech Products Fund
— Adam Feuerstein (@adamfeuerstein) December 10, 2014
$BLUE should change its ticker symbol to $GREEN.
— Roy Friedman (@DewDiligence) December 10, 2014
RT @pharmamaven: $CELG Abraxane SA BreastCncr Sym Late Breaker abstract is out (not widely distributed yet) &VERY positive. @dsobek
— happycamper (@happyycamperr) December 10, 2014
.@GantosJ $ZGNX reaching $1.20 with MACD crossover & +ve RSI... next is breaking out the 50MA around $1.25
— Joe (@GantosJ) December 10, 2014
$blue MCap ~$2.5B; $kite ~$2B. $juno not even around yet. #whoa
What would $kite be if they DIDN'T have an offering & IPO lockup exp?
— Joe (@Drchik23) December 10, 2014
I’ve got one hell of a mess to unwind if $ACHN data hits NEXT week & meets expectations. Lucrative mess, still a mess.
— Jake King (@FajaJake) December 10, 2014
I love a good 30% move from an in-licensing deal for a pre-clinical asset #biobubble
— Jonathan Mandelbaum (@biotechbaumer) December 10, 2014
@probioinvest bioturds are the best. indifferent to market conditions
— DeadCatBill (@getbillasap) December 10, 2014
@stockmannick Even more impressive to see stocks with a pending secondary green on a day like today. $KITE $AGIO
— David Sobek (@dsobek) December 10, 2014
Not to hype it, and I know this isn't going out on a limb, but put me on record saying the $JUNO opening will be dotcom bubble silly.
— Brad Loncar (@bradloncar) December 11, 2014
How hot is biotech right now? $AGIO and $KITE announce offerings yesterday, both price above the close yesterday with VERY red markets today
— Shane Blackmon (@shaneblackmon) December 11, 2014
In a market like this, $ will follow the hot hand w catalyst. $ssh is the inverse of that. Great opp here. It'll run eventually
— Randy (@lipscrl) December 11, 2014
$ONVO was on FastMoney, and of course all the traders love it and think it's big pharma bait. One says stock could go $25. Oh brother.
— Brad Loncar (@bradloncar) December 11, 2014
Market is nuts
— Randy (@lipscrl) December 11, 2014
unlike $BLUE I think im the only person on my twitter feed long $CCXI
— Dan Rosenblum (@sharkbiotech) December 12, 2014
Ok fellows that's it - decided I'll hold through $ASPX results w full position. This was a good year I feel I can afford to risk that amt
— Alfredo Fontanini (@AF_biotech) December 12, 2014
#Biotech Data Events by YE14
$ACHN Nuc
$ARGS HIV
$ASPX Ph3
$CNAT ACLF
$PBYI NSABP
$RDUS Ph3
$TLOG Ovarian
$XNCR Ph2a RA
$IMGN/Roche MARIANNE
— Andy Biotech (@AndyBiotech) December 12, 2014